Iovance Biotherapeutics Inc (LTS:0JDK)
$ 11.29 0.295 (2.68%) Market Cap: 3.48 Bil Enterprise Value: 3.15 Bil PE Ratio: 0 PB Ratio: 4.43 GF Score: 30/100

Q3 2019 Iovance Biotherapeutics Inc Earnings Call Transcript

Nov 04, 2019 / 09:30PM GMT
Release Date Price: $21.75
Operator

Good afternoon, and welcome to the Iovance Biotherapeutics Third Quarter 2019 Financial Results Conference Call. (Operator Instructions)

Please be advised that the call is being recorded at the company's request.

Now I would like to turn the call over to Tim Morris, Chief Financial Officer at Iovance. Sir, please go ahead.

Timothy E. Morris
Iovance Biotherapeutics, Inc. - CFO, Principal Accounting Officer, Corporate Secretary & Treasurer

Thank you, operator. Good afternoon, everyone, and thank you for joining us. With me on the call is Maria Fardis, our President and Chief Executive Officer; and Friedrich Finckenstein, our Chief Medical Officer. This afternoon, we issued a press release that you can find on our website at iovance.com, which includes the financial results for the third quarter and 9 months ended September 30, 2019, as well as the company update.

Before we start, I would like to remind everyone that statements made during this conference call will include forward-looking statements regarding Iovance's goals,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot